NFKB1 and cholangiocarcinoma: For example, in pancreas cancer 32, Wang and his colleague found Escin potentiated the antitumor activity of gemcitabine via the inactivation of NF‐κB. While in cholangiocarcinoma 22, Escin was found to reverse P‐gp‐dependent multidrug resistance via inhibition of the GSK3β/β–catenin pathway.